PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
CNCR vs. HTUS
Performance
Return for Risk
Drawdowns
Volatility
Dividends

CNCR vs. HTUS

Last updated Jun 24, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and HTUS (Hull Tactical US ETF) are both exchange-traded funds - CNCR is a Health & Biotech Equities fund tracking the Loncar Cancer Immunotherapy Index, while HTUS is a Long-Short fund actively managed by Exchange Traded Concepts. CNCR is passively managed, while HTUS is actively managed. CNCR charges 0.79%/yr vs 0.97%/yr for HTUS.

Performance

CNCR vs. HTUS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Hull Tactical US ETF (HTUS). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

CNCR

1D
0.00%
1M
0.00%
YTD
—
6M
—
1Y
—
3Y*
—
5Y*
—
10Y*
—

HTUS

1D
-1.20%
1M
-0.99%
YTD
8.95%
6M
8.55%
1Y
24.12%
3Y*
20.35%
5Y*
14.66%
10Y*
12.20%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. HTUS - Yearly Performance Comparison

2026 (YTD)
CNCR
Loncar Cancer Immunotherapy ETF		0.00%
HTUS
Hull Tactical US ETF		9.51%

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Loncar Cancer Immunotherapy ETF

Hull Tactical US ETF

Often compared with CNCR:
CNCR vs. SCHDCNCR vs. XBICNCR vs. IYHCNCR vs. IBBQCNCR vs. SMHCNCR vs. SPMOCNCR vs. VB
Often compared with HTUS:
HTUS vs. SPYHTUS vs. CLSEHTUS vs. ARGTHTUS vs. FTLSHTUS vs. DFNDHTUS vs. LBAYHTUS vs. VTV

Return for Risk

CNCR vs. HTUS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
CNCR

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

HTUS
HTUS Risk / Return Rank: 6868
Overall Rank
HTUS Sharpe Ratio Rank: 6565
Sharpe Ratio Rank
HTUS Sortino Ratio Rank: 6868
Sortino Ratio Rank
HTUS Omega Ratio Rank: 6969
Omega Ratio Rank
HTUS Calmar Ratio Rank: 5959
Calmar Ratio Rank
HTUS Martin Ratio Rank: 7676
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. HTUS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Hull Tactical US ETF (HTUS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

CNCRHTUSDifference
Sharpe ratioReturn per unit of total volatility

—

2.02

—

Sortino ratioReturn per unit of downside risk

—

2.95

—

Omega ratioGain probability vs. loss probability

—

1.39

—

Calmar ratioReturn relative to maximum drawdown

—

2.79

—

Martin ratioReturn relative to average drawdown

—

13.82

—

CNCR vs. HTUS - Sharpe Ratio Comparison

Loading charts...

Drawdowns

CNCR vs. HTUS - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum HTUS drawdown of -47.50%. Use the drawdown chart below to compare losses from any high point for CNCR and HTUS.

Loading charts...

Drawdown Indicators

CNCRHTUSDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-47.50%

+47.50%

Max Drawdown (1Y)

Largest decline over 1 year

—

-8.68%

—

Max Drawdown (3Y)

Largest decline over 3 years

—

-24.41%

—

Max Drawdown (5Y)

Largest decline over 5 years

—

-24.41%

—

Max Drawdown (10Y)

Largest decline over 10 years

—

-47.50%

—

Current Drawdown

Current decline from peak

0.00%

-2.67%

+2.67%

Average Drawdown

Average peak-to-trough decline

0.00%

-4.05%

+4.05%

Ulcer Index

Depth and duration of drawdowns from previous peaks

—

1.75%

—

Volatility

CNCR vs. HTUS - Volatility Comparison

Loading charts...

Volatility by Period

CNCRHTUSDifference

Volatility (1M)

Calculated over the trailing 1-month period

—

4.02%

—

Volatility (6M)

Calculated over the trailing 6-month period

—

10.00%

—

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

12.04%

-12.04%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

19.09%

-19.09%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

21.49%

-21.49%

CNCR vs. HTUS - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is lower than HTUS's 0.97% expense ratio.

Dividends

CNCR vs. HTUS - Dividend Comparison

CNCR has not paid dividends to shareholders, while HTUS's dividend yield for the trailing twelve months is around 10.91%.

PositionTTM2025202420232022202120202019201820172016
CNCR
Loncar Cancer Immunotherapy ETF		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
HTUS
Hull Tactical US ETF		10.91%11.89%17.80%1.18%5.63%7.20%3.77%0.92%8.69%8.29%3.02%

Frequently Asked Questions

On fees, CNCR is cheaper at 0.79% per year. The better choice depends on whether you care most about return, fees, risk, or income.

CNCR is cheaper with a 0.79% expense ratio, compared with 0.97% for HTUS.

HTUS has the higher dividend yield at 10.91%, compared with 0.00% for CNCR.

CNCR is categorized as Health & Biotech Equities, while HTUS is Long-Short. Their fees differ too: 0.79% for CNCR and 0.97% for HTUS.

Portfolio Optimizer

Find the right allocation for CNCR and HTUS

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer